Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,930Revenue $M260Net Margin (%)15.4Z-Score33.8
Enterprise Value $M9,193EPS $0.9Operating Margin %20.4F-Score5
P/E(ttm))121Cash Flow Per Share $0.2Pre-tax Margin (%)20.4Higher ROA y-yN
Price/Book13.710-y EBITDA Growth Rate %0Quick Ratio5.7Cash flow > EarningsY
Price/Sales18.15-y EBITDA Growth Rate %0Current Ratio6.0Lower Leverage y-yY
Price/Cash Flow306y-y EBITDA Growth Rate %121ROA % (ttm)11.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)13.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M75.5ROI % (ttm)2.8Gross Margin Increase y-yN

Gurus Latest Trades with PCYC

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCYCKen Fisher 2014-09-30 Reduce$91.5 - $127.81
($114.49)
$ 131.4515%Reduce -36.57%3,244
PCYCJoel Greenblatt 2014-09-30 Sold Out -0.09%$91.5 - $127.81
($114.49)
$ 131.4515%Sold Out0
PCYCJoel Greenblatt 2014-06-30 Add0.08%$85.85 - $107.42
($93.89)
$ 131.4540%Add 724.62%79,089
PCYCKen Fisher 2014-06-30 Buy $85.85 - $107.42
($93.89)
$ 131.4540%New holding, 5114 sh.5,114
PCYCMariko Gordon 2014-06-30 Sold Out -0.04%$85.85 - $107.42
($93.89)
$ 131.4540%Sold Out0
PCYCMariko Gordon 2014-03-31 Add0.02%$100.49 - $151.61
($129.71)
$ 131.451%Add 112.41%9,295
PCYCJoel Greenblatt 2014-03-31 Buy 0.01%$100.49 - $151.61
($129.71)
$ 131.451%New holding, 9591 sh.9,591
PCYCMariko Gordon 2013-12-31 Add0.01%$99.28 - $139.59
($121.32)
$ 131.458%Add 130.07%4,376
PCYCMariko Gordon 2013-09-30 Buy 0.01%$84.5 - $132.49
($110.93)
$ 131.4518%New holding, 1902 sh.1,902
PCYCJoel Greenblatt 2013-03-31 Sold Out -0.14%$57.78 - $94.2
($77.47)
$ 131.4570%Sold Out0
PCYCJoel Greenblatt 2012-12-31 Buy 0.14%$47.87 - $69.78
($58.72)
$ 131.45124%New holding, 41832 sh.41,832
PCYCGeorge Soros 2012-06-30 Sold Out -0.04%$25.72 - $53.44
($32.62)
$ 131.45303%Sold Out0
PCYCGeorge Soros 2012-03-31 Buy 0.04%$14.99 - $28.68
($20.91)
$ 131.45529%New holding, 100000 sh.100,000
PCYCPRIMECAP Management 2011-06-30 Add0.01%$5.66 - $10.63
($7.17)
$ 131.451733%Add 21.34%4,011,958
PCYCPRIMECAP Management 2010-06-30 Add0.01%$5.53 - $8.18
($6.98)
$ 131.451783%Add 43.36%3,306,481
PCYCPRIMECAP Management 2009-09-30 Add$1.2299 - $2.32
($1.49)
$ 131.458722%Add 51.48%2,300,678
PCYCPRIMECAP Management 2009-06-30 Reduce$1.02 - $1.39
($1.24)
$ 131.4510501%Reduce -27.71%1,518,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCYC is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PCYC PRIMECAP Management 2014-09-302,311,0393.060.29-0.09%
PCYC Ken Fisher 2014-09-303,24400-36.57%
PCYC Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PCYC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fardis MariaChief of Oncology Ops & Allian 2014-11-13Sell3,000$141.3-6.97view
Soni Manmeet SinghCFO 2014-11-13Sell1,000$141.44-7.06view
Zanganeh MakyCOO 2014-11-12Sell30,482$134.69-2.41view
Love Richard BGeneral Counsel 2014-11-10Sell1,500$133.87-1.81view
Fardis MariaChief of Oncology Ops & Allian 2014-11-07Sell5,000$134.5-2.27view
Zanganeh MakyCOO 2014-09-04Sell12,000$121.757.97view
Love Richard BGeneral Counsel 2014-08-27Sell1,500$1246.01view
Fardis MariaChief of Oncology Ops & Allian 2014-08-13Sell4,000$121.018.63view
Tan HeowChief Quality&Tech Operations 2014-08-13Sell10,000$123.586.37view
McGreivy JesseChief Medical Officer 2014-08-07Sell34,062$120.928.71view

Press Releases about PCYC :

    Quarterly/Annual Reports about PCYC:

    News about PCYC:

    Articles On GuruFocus.com
    Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
    comment on PCYC Mar 06 2013 
    Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 
    Pharmacyclics Inc. Reports Operating Results (10-Q) Feb 08 2011 
    Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 09 2010 
    Weekly CEO Buys Highlight: Pharmacyclics Inc, Saul Centers Inc, Charming Shoppes Inc, ProLogis, Exce Jun 27 2010 
    Pharmacyclics Inc. Reports Operating Results (10-Q) May 07 2010 
    cooldecency99 note on PCYC May 01 2010 
    cooldecency99 note on PCYC May 01 2010 
    Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 03 2009 

    More From Our Partners
    Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day Dec 19 2014 - ZACKS

    More From Other Websites
    Pharmacyclics Named 2014 Outstanding Company by BayBio Dec 12 2014
    Pharmacyclics Named 2014 Outstanding Company by BayBio Dec 12 2014
    PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 11 2014
    Pharmacyclics Presents Imbruvica Data at the ASH Meeting Dec 09 2014
    UPDATE - IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk... Dec 09 2014
    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with... Dec 09 2014
    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 09 2014
    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 09 2014
    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 08 2014
    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 08 2014
    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 08 2014
    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with... Dec 08 2014
    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 08 2014
    Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Dec 08 2014
    Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical... Dec 08 2014
    IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma Dec 06 2014
    IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma Dec 06 2014
    Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL)... Dec 05 2014
    Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL)... Dec 05 2014
    Biotech stocks to watch at ASH Dec 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK